CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 5, 2024 4:01 PM EDT-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 20 patients have had cells collected across all regions as of mid-July-
-Clinical trials ongoing for next generation CAR T product candidates, CTX112 and CTX131 targeting CD19 and CD70 respectively, across multiple indications-
-Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) and for CTX131 in hematological malignancies-
-Clinical trials ongoing for in vivo gene editing product candidates, CTX310 and CTX320 targeting ANGPTL3 and LPA, respectively-
-Clinical... More
